GSK plc (GSK) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$50.50
Price Target
$52.45
Target Range
$35.25 — $85.00
Analyst Rating
Hold
Forward P/E10.4x
Trailing P/E6.7x
Forward PEG0.73
Implied Growth+54.1%
Median Target$53.00
Analyst Spread94.9%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$35
-30.2%
Consensus
$52
+3.9%
Bull Case
$85
+68.3%
Valuation Model TargetsConfidence: 54/100
Bear$13
Base$24
Bull$44
GSK Price Target Analysis
Updated May 8, 2026As of May 8, 2026, GSK plc (GSK) has a Wall Street consensus price target of $52.45, based on estimates from 29 covering analysts. With the stock currently trading at $50.50, this represents a potential upside of +3.9%. The company has a market capitalization of $101.56B.
Analyst price targets range from a low of $35.25 to a high of $85.00, representing a 95% spread in expectations. The median target of $53.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 9 analysts rating the stock as a Buy or Strong Buy,16 rating it Hold, and 4 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, GSK trades at a trailing P/E of 6.7x and forward P/E of 10.4x. The forward PEG ratio of 0.73 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +54.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $24.35, with bear and bull scenarios of $12.98 and $43.73 respectively. Model confidence stands at 54/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+13.4%
Avg Forward P/E16.8x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 AZNAstraZeneca PLC | $283.0B | $182.52 | $211.00 | +15.6% | Buy | 17.7x | 41 |
 NVSNovartis AG | $277.4B | $145.39 | $141.00 | -3.0% | Hold | 16.6x | 25 |
 SNYSanofi | $104.3B | $43.18 | $50.00 | +15.8% | Buy | 10.3x | 27 |
 PFEPfizer Inc. | $150.6B | $26.48 | $27.27 | +3.0% | Hold | 8.9x | 39 |
 MRKMerck & Co., Inc. | $277.3B | $112.29 | $129.31 | +15.2% | Buy | 21.9x | 37 |
 BMYBristol-Myers Squibb Company | $114.8B | $56.25 | $62.00 | +10.2% | Hold | 8.9x | 41 |
 LLYEli Lilly and Company | $921.2B | $974.96 | $1258.47 | +29.1% | Buy | 28.2x | 45 |
 ABBVAbbVie Inc. | $358.4B | $202.64 | $256.64 | +26.6% | Buy | 14.3x | 41 |
 JNJJohnson & Johnson | $536.2B | $222.51 | $249.27 | +12.0% | Buy | 19.2x | 40 |
 HLNHaleon plc | $41.4B | $9.31 | $10.20 | +9.6% | Buy | 22.2x | 4 |
Upside Potential Comparison
LLYABBVSNYAZNMRKJNJBMYHLNFull GSK Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See GSK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GSK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GSK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGSK — Frequently Asked Questions
Quick answers to the most common questions about buying GSK stock.
What is the GSK stock price target for 2026?
The consensus price target for GSK is $52.45, close to the current price of $50.5 (3.9% implied move). Based on 29 analyst estimates, the stock appears fairly valued near current levels.
Is GSK a buy, sell, or hold?
GSK has a consensus rating of "Hold" based on 29 Wall Street analysts. The rating breakdown is mixed, with 16 Hold ratings making up the largest segment. The consensus 12-month price target of $52.45 implies 3.9% upside from current levels.
Is GSK stock overvalued or undervalued?
With a forward P/E of 10.4319x, GSK trades at a relatively low valuation. The consensus target of $52.45 implies 3.9% appreciation, suggesting the market may be pricing in risks.
How high can GSK stock go?
The most bullish Wall Street analyst has a price target of $85 for GSK, while the most conservative target is $35.25. The consensus of $52.45 represents the median expectation. Our quantitative valuation model projects a bull case target of $44 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover GSK stock?
GSK is heavily covered by Wall Street, with 29 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 16 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the GSK stock forecast?
The 12-month GSK stock forecast based on 29 Wall Street analysts shows a consensus price target of $52.45, with estimates ranging from $35.25 (bear case) to $85 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $24, with bear/bull scenarios of $13/$44.
What is GSK's fair value based on fundamentals?
Our quantitative valuation model calculates GSK's fair value at $24 (base case), with a bear case of $13 and bull case of $44. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 54/100.
What is GSK's forward P/E ratio?
GSK trades at a forward P/E ratio of 10.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 6.7x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy GSK stock?
GSK appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $52.45 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do GSK price targets vary so much?
GSK analyst price targets range from $35.25 to $85, a 95% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $52.45 consensus represents the middle ground. Our model's $13-$44 range provides an independent fundamental perspective.